| dc.description.abstract | Tuberculosis (TB) is the 9th leading cause of death around the world. Multi-Drug resistance(MDR-TB) i.e resistance to both isoniazid and rifampicin is one of the serious obstacle in the treatmeant of TB. About 3.4 percent of new TB patients and 20% of patients who had already received TB therapy were diagnosed with MDR-TB globally. MDR-TB treatment is a complex, time-consuming process and requires multiple medication including second-line drugs which have unfavourable outcomes. However, treatment outcomes have been enhanced with the introduction of new agents (bedaquiline, delamanid and pretomanid). In 2018, WHO isssued a swift contact and in 2019 revised guidelines were released. The new recommendations includes the reclassification of the second line drugs, regimen building that contains new drugs and repurposed agents. The objective of this article is to analyse the treatment strategies of MDR-TB and diagnostic techniques based on WHO 2019 revised guidelines. | en_US |
